Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design programprotobuild
Novel indole compounds which interact with peroxisome proliferator-activated receptors (PPARs) are disclosed. The compounds have an influence on metabolic diseases, obesity and diabetes.